加倍剂量福辛普利强化治疗蛋白尿的研究

目的:研究加倍剂量福辛普利对蛋白尿的强化治疗作用及其安全性。方法:原发性肾病患者随机分为2组,分别给予福辛普利10mg、20mg治疗12周,每3周检测尿蛋白、血压、血钾、血肌酐。结果:①12周后加倍剂量组尿蛋白下降幅度达(57.9±5.1)%,显著高于单倍剂量组(41.5±3.5)% (P<0.01);②两组血压均有显著下降,但两组间无显著差异;③两组血清肌酐、血钾无明显差异。结论:加倍剂量福辛普利较单倍剂量福辛普利有更好的降蛋白尿作用,且加倍剂量对血压能进一步下降但无统计学差异,对肾功能和血钾无不良影响。

Effect of Proteinuria Treated with Intensive Double Doses of Fosinopril Therapy

Objective:To investigate the antiproteinuric effect and safety of double doses of fosinopril by a randomized controlled study.Methods:The patients with primary glomerular diseases were randomly divided into two groups and used fosinopril in two different dosages(10mg/d and 20mg/d) for 12 weeks.Blood pressure,proteinuria,serum creatinine,and serum potassium were measured every 3 weeks.Results:(1)Double doses of fosinopril exerted more significant aniproteinuric effect compared to the single dose group [(57.9±5.1)% vs(41.5±3.5)%,P<0.01] after 12 weeks treatment.(2) The blood preasure reduction between the two groups had no remarkable difference(P>0.05).(3)During observation period,serum creatinine and serum potassium in double doses group had no significant increase compared to the single dose group.Conclusion:The double doses of fosinopril had an superior aniproteinuric effect than the single dose and it is secure.